Ranked only against the same measurement, in the same unit. See the positive, neutral, opposite-direction and still-collecting evidence before deciding what is worth your own test.
Phoenix APOE4 Research · Reviewed by Kevin Tran, APOE4/4 carrier and founder · Data through 2026-08-23 · How to read this research
How to read this
Observational research: real APOE4 carriers tracked over time, each compared with their own earlier self. Members chose their interventions, with no randomisation or placebo group. Everything else they changed is shown beside each result.
Read the full methods and limitsRead the 43-page study: what members tried, how their results changed, and what else they changed at the same time.
Data through 2026-08-23
Enter your APOE status and email to unlock every result and get the 43-page PDF.
For APOE4 carriers, Phoenix has published positive evidence for Berberine, Metformin, and Tirzepatide against Insulin. Member #EFF528's Insulin moved from 2.3 to 2.1 uIU/mL in 207 days. Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated. Member #6FAEFA's Insulin moved from 6.3 to 4.2 uIU/mL in 70 days.
Phoenix has measured 3 interventions against Insulin: 3 positive. See the table below.
| Intervention | What we observed | Evidence status |
|---|---|---|
| Berberine | Member #EFF528's Insulin moved from 2.3 to 2.1 uIU/mL in 207 days. | Positive individual result |
| Metformin | Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated. | Positive individual result |
| Tirzepatide | Member #6FAEFA's Insulin moved from 6.3 to 4.2 uIU/mL in 70 days. | Positive individual result |
Turn evidence into your next test
476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.
Full research index
Choose an outcome, like LDL cholesterol or sleep, or an intervention, like training: both paths open the same measured records.